Cohance Lifesciences Q2 FY27 Results: Consolidated Net Profit ₹2.27 Crore on Total Income of ₹489 Crore

Cohance Lifesciences (NSE: COHANCE) reported consolidated total income of ₹489.06 crore and consolidated net profit of ₹2.27 crore for the quarter ended 30 Sep 2026, it said in a filing on 06 Nov 2026. Net profit attributable to shareholders was ₹15.22 crore, and consolidated profit before tax was negative at ₹10.75 crore. Standalone total income was ₹437.26 crore and standalone net profit ₹13.27 crore.

Key highlights

Summary

Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

Consolidated net profit fell 96.6% year on year, a larger fall than the 14.4% decline in total income.

Revenue from operations of ₹476.65 crore fell 14.2% year on year, less than other income, which fell 20.4% to ₹12.41 crore. Other income is 2.5% of total income this quarter and finance costs of ₹8.37 crore are 1.7% of total income, so the quarter's result rests mainly on operating revenue. Depreciation rose 14.0% to ₹50.17 crore while revenue fell.

In the prior quarter the attributable figure was a loss of ₹24.12 crore. The filing does not give the reason for the fall in profit before tax to a loss.

Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

Standalone net profit fell 85.9% year on year to ₹13.27 crore, against a 16.6% fall in total income. Profit before tax was a loss of ₹0.26 crore, against a profit of ₹120.72 crore a year earlier, and a tax credit of ₹13.53 crore lifted net profit above that level. Standalone revenue from operations fell 16.3% to ₹416.69 crore, less than other income, which fell 21.8% to ₹20.57 crore.

Standalone other income of ₹20.57 crore is 4.7% of total income, and finance costs of ₹3.35 crore are 0.8% of total income, down 36.1% from a year earlier. Against the prior quarter, standalone net profit rose 841.1% from ₹1.41 crore while total income rose 17.5%.

Consolidated net profit of ₹2.27 crore is ₹11.00 crore lower than standalone net profit of ₹13.27 crore, while consolidated total income is ₹51.80 crore higher than standalone. The difference between the two sets of results is not explained in the filing beyond the subsidiary and minority figures in the notes.

Inference

The filing records an acquisition of an additional 65% in Aaruka Bio Inc for ₹47.89 crore and an additional 11.3% in NJ Bio Inc for ₹124.40 crore, which took its holding to 67.3%. It also records a proposed 26% equity investment in a solar power SPV, with cash consideration of about ₹5.72 crore, and the company says the SPV is for captive consumption of renewable power.

After the period end, the Sapala Organics holding was reduced from 67.5% to 51% on conversion of CCPS, and a Telangana Pollution Control Board order dated 5 Nov 2026 directed closure of operations at the Suryapet facility after an industrial accident with a fatality. The filing does not say what financial effect the closure will have, how long it will last, or when the company expects to resume operations.

The filing does not give a reason for the fall in consolidated profit before tax, and it does not say whether Dr. Kuber Jagdale's appointment as Chief Technical Officer and Executive Director has been approved by shareholders. Company CEO Umang Vohra expects H2 FY27 to be materially stronger than H1, with year-on-year growth in revenue and EBITDA; that is the company's expectation and not a figure in the filing.